title: Study on clinical characteristics and follow-up visit of acquired aplastic anemia associated with parvovirus B19 infection.
abstract: OBJECTIVE
  To investigate clinical characteristics of parvovirus (B19) related aplastic anemia (AA).
  
  
  METHODS
  Of the 28 children with AA included in this study, 24 were treated routinely and received planned follow-up; 15 were subject to B19-DNA re-examination during the treatment and 8 underwent examination for B19-IgM and B19-IgG. Another 39 initially identified AA children were enrolled as the controls and received the treatment same as the above-mentioned group.
  
  
  RESULTS
  There were more patients aged 5-8 y in the B19 infection group than the control group (P < 0.05). The course of AA in the B19 infection group was less than 2 mo and the serious aplastic anemia (SAA) and very serious aplastic anemia (VSAA) were more frequently observed in this group than the controls (P < 0.05). The overall efficacy of the treatments in the B19 infection group was more dismal than that in the controls (P < 0.05). Among 15 patients who were subjected to B19-DNA re-examination, negative findings were found in 6 patients with chronic aplastic anemia (CAA); the B19-DNA was persistently positive in 2 of the SAA and 5 VSAA patients. IgM and IgG were respectively detected in 3 and 2 patients out of the 8 children who received antibody examination.
  
  
  CONCLUSIONS
  Parvovirus B19 infection contributes to the generation of AA, particularly in children aged 5-8 y. The AA induced may be mainly classified as serious and very serious type, with a course of disease less than 2 mo. Patients can be saved if B19-DNA is eliminated and the antibody is produced.
authors.affiliation: Children Disease Research Deparment, Xi'an Childern Hospital, Xi'an, Shanxi, People's Republic of China. wenjinquan@163.com
authors.forename: Jin-quan
authors.initials: JQ
authors.lastname: Wen
authors.forename: Nan
authors.initials: N
authors.lastname: Zhou
authors.forename: Dan
authors.initials: D
authors.lastname: Li
authors.forename: Hai-ling
authors.initials: HL
authors.lastname: Feng
authors.forename: Hua
authors.initials: H
authors.lastname: Wang
mesh_terms: D000293:Adolescent; D000741:Anemia, Aplastic / Q000175:diagnosis / Q000188:drug therapy / Q000821:virology*; D000914:Antibodies, Viral / Q000097:blood; D016022:Case-Control Studies; D002648:Child; D002675:Child, Preschool; D002908:Chronic Disease; D004279:DNA, Viral / Q000302:isolation & purification; D004359:Drug Therapy, Combination; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D016756:Immunoglobulins, Intravenous / Q000627:therapeutic use; D007155:Immunologic Factors / Q000627:therapeutic use; D008297:Male; D010322:Parvoviridae Infections / Q000150:complications* / Q000175:diagnosis / Q000188:drug therapy / Q000821:virology; D016732:Parvovirus B19, Human / Q000235:genetics / Q000276:immunology / Q000302:isolation & purification; D012720:Severity of Illness Index; D016896:Treatment Outcome
chemical_list: D000914:Antibodies, Viral; D004279:DNA, Viral; D016756:Immunoglobulins, Intravenous; D007155:Immunologic Factors